Developing and Piloting an Implementation Strategy for a Brief, Motivational Interviewing-based Lethal Means Safety Counseling Intervention in Primary Care Settings (CDA-2)

November 20, 2025 updated by: VA Office of Research and Development
Suicide prevention remains a significant priority and nearly three-quarters of Veteran suicides result from firearm injury. Since access to lethal means of self-harm increases the risk of injury, the VA/DoD Clinical Practice Guidelines recommend that Veterans with elevated suicide risk receive lethal means safety (LMS) counseling to reduce access to lethal means, including firearms. However, no LMS counseling interventions have been tested within VA. Thus, the aim of this study is to conduct a pilot randomized controlled trial to evaluate the feasibility and acceptability of a tailored LMS counseling intervention compared to an active control condition.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This is a pilot randomized controlled trial of up to 50 Veterans to assess the feasibility and acceptability of a LMS intervention and testing procedures.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Connecticut
      • West Haven, Connecticut, United States, 06516-2770
        • VA Connecticut Healthcare System West Haven Campus, West Haven, CT
        • Contact:
        • Contact:
        • Principal Investigator:
          • Frances Aunon, PhD MS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

For Veterans:

  • Has access to a firearm
  • Referred to PCMHI care

For clinicians (delivering intervention):

  • deliver care in PCMHI
  • trained in RAMP and study procedures

Exclusion Criteria:

For Veterans:

  • Unable to consent due to cognitive impairment, severity of illness (including psychiatric symptoms), intoxication with drugs and/or alcohol
  • Unreliable telephone access
  • Inability to read English or communicate in spoken and written English

For clinicians (delivering intervention):

- Did not participate in training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Active control
The control condition will entail a 5-minute review of a pamphlet on suicide prevention with the PCMHI clinician. This pamphlet is produced by the Veteran's Crisis Line and is widely available on the OSP suicide prevention website as a VHA resource. This condition will control for time and attention, subject matter, mode of delivery, and setting.
The control condition will entail a 5-minute review of a pamphlet on suicide prevention with the PCMHI clinician. This pamphlet is produced by the Veteran's Crisis Line and is widely available on the OSP suicide prevention website as a VHA resource. This condition will control for time and attention, subject matter, mode of delivery, and setting.
Experimental: RAMP
Participants randomized to the intervention condition will receive a brief, motivational interviewing-based intervention called RAMP (Raise the subject, Assess current storage, Motivate change, and Plan next steps) in the context of their clinical care. RAMP incorporates evidence-informed intervention components to facilitate secure firearm storage
Participants randomized to the intervention condition will receive a brief, motivational interviewing-based intervention called RAMP (Raise the subject, Assess current storage, Motivate change, and Plan next steps) in the context of their clinical care. RAMP incorporates evidence-informed intervention components to facilitate secure firearm storage

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Screening
Time Frame: through study completion, approximately 2 years
Investigators will assess the number of new PCMHI patients seen in PCMHI and the number who were approached about potential study participation per month
through study completion, approximately 2 years
Recruitment
Time Frame: through study completion, approximately 2 years
Investigators will track the number of eligible Veterans who enrolled in the study per month
through study completion, approximately 2 years
Retention
Time Frame: approximately 30 days
Investigators will calculate the number of Veterans who received RAMP who were willing to complete immediate and one-month follow up assessments.
approximately 30 days
Assessment of behavioral outcomes
Time Frame: approximately 30 days
Investigators will assess the percentage of participants who completed behavioral outcome measures within the time allotted at each timepoint
approximately 30 days
Veteran acceptability - Theoretical Framework of Acceptability
Time Frame: At immediate follow up, within approximately 2 weeks of intervention
Investigators will assess Veteran acceptability using the eight Likert-style items from the Theoretical Framework of Acceptability questionnaire, which assess seven component constructs of acceptability including Veteran's experience of the lethal means safety intervention. Each item has 5 answer options (1-5) on a Likert Scale. Score range is 8 to 40, with a higher score indicating more higher reported acceptability.
At immediate follow up, within approximately 2 weeks of intervention
Veteran acceptability - Experience and Satisfaction with intervention
Time Frame: At immediate follow up, within approximately 2 weeks of intervention
Investigators will conduct qualitative evaluation of the participant's experience and satisfaction receiving the intervention.
At immediate follow up, within approximately 2 weeks of intervention
Clinician acceptability - Theoretical Framework of Acceptability
Time Frame: at 50% enrollment (approximately 1 year) and 100% enrollment (approximately 2 years)
Investigators will invite clinicians to respond to the eight-item Theoretical Framework of Acceptability questionnaire eliciting clinician acceptability of the lethal means safety intervention. Each item has 5 answer options (1-5) on a Likert Scale. Score range is 8 to 40, with a higher score indicating more higher reported acceptability.
at 50% enrollment (approximately 1 year) and 100% enrollment (approximately 2 years)
Clinician acceptability - Negative impact
Time Frame: at 50% enrollment (approximately 1 year) and 100% enrollment (approximately 2 years)
Investigators will assess to what extent PCMHI clinicians agree that study recruitment negatively impacted clinical care, using Likert-type items where '1' indicates "strongly disagree" and '5' indicates "strongly agree." For those responding >3 ("don't know"), an open-ended question will elicit detailed information (e.g., interfered with delivery of clinical care, led to Veteran frustration).
at 50% enrollment (approximately 1 year) and 100% enrollment (approximately 2 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frances Aunon, PhD MS, VA Connecticut Healthcare System West Haven Campus, West Haven, CT

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2027

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 31, 2031

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

November 20, 2025

First Posted (Actual)

November 25, 2025

Study Record Updates

Last Update Posted (Actual)

November 25, 2025

Last Update Submitted That Met QC Criteria

November 20, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide Prevention

Clinical Trials on Active control

Subscribe